{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:23:21Z","timestamp":1781796201622,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejso.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ejso.2019.01.219","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T01:45:32Z","timestamp":1548985532000},"page":"969-975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype"],"prefix":"10.1016","volume":"45","author":[{"given":"Rosa","family":"Di Micco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fiacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Carriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ilaria","family":"Gattuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Nazzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Panizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gianolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Canevari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Di Muzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Sassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milvia","family":"Zambetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreste D.","family":"Gentilini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejso.2019.01.219_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12609-013-0135-7","article-title":"Use of sentinel lymph node biopsy to select patients for local-regional therapy after neoadjuvant chemotherapy","volume":"6","author":"Erdahl","year":"2014","journal-title":"Curr Breast Cancer Rep"},{"issue":"1","key":"10.1016\/j.ejso.2019.01.219_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","author":"(EBCTCG), E.B.C.T.C.G.","year":"2018","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ejso.2019.01.219_bib3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","article-title":"Axillary nodal management following neoadjuvant chemotherapy: a review","volume":"3","author":"Pilewskie","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2019.01.219_bib4","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"15","author":"Fisher","year":"1997","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejso.2019.01.219_bib5","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","article-title":"The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"21","author":"Bear","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2019.01.219_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2019.01.219_bib7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/bjs.5209","article-title":"Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer","volume":"93","author":"Xing","year":"2006","journal-title":"Br J Surg"},{"issue":"18","key":"10.1016\/j.ejso.2019.01.219_bib8","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1016\/j.ejca.2009.08.001","article-title":"Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review","volume":"45","author":"van Deurzen","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ejso.2019.01.219_bib9","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/1097-0142(20001201)89:11<2187::AID-CNCR6>3.0.CO;2-#","article-title":"Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma","volume":"89","author":"Nason","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2019.01.219_bib10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1524-4741.2002.08205.x","article-title":"Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer","volume":"8","author":"Brady","year":"2002","journal-title":"Breast J"},{"issue":"3","key":"10.1016\/j.ejso.2019.01.219_bib11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2014.58.9838","article-title":"Appropriate role for sentinel node biopsy after neoadjuvant chemotherapy in patients with early-stage breast cancer","volume":"33","author":"Lyman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejso.2019.01.219_bib12","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2217\/fon-2018-0132","article-title":"Sentinel lymph node biopsy management after neoadjuvant treatment for breast cancer care","volume":"14","author":"Corso","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejso.2019.01.219_bib13","article-title":"Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update","author":"Lyman","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2019.01.219_bib14","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2019.01.219_bib15","first-page":"1087","article-title":"Clinical utility of ultrasound-needle biopsy for preoperative staging of the axilla in invasive breast cancer","volume":"34","author":"Houssami","year":"2014","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.ejso.2019.01.219_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2015.63","article-title":"Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy","volume":"12","author":"King","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejso.2019.01.219_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.breast.2017.06.004","article-title":"Less is more. Breast conservation might be even better than mastectomy in early breast cancer patients","volume":"35","author":"Gentilini","year":"2017","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.ejso.2019.01.219_bib18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10549-016-4006-6","article-title":"Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)","volume":"160","author":"Golshan","year":"2016","journal-title":"Breast Canc Res Treat"},{"issue":"22","key":"10.1016\/j.ejso.2019.01.219_bib19","first-page":"1029","article-title":"Clear-cut beneficial effect of breast cancer screening on the trend in breast-conserving surgery","volume":"146","author":"van der Hage","year":"2002","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"30","key":"10.1016\/j.ejso.2019.01.219_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18","author":"Wolmark","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ejso.2019.01.219_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fonc.2012.00125","article-title":"Breast cancer: from \"maximum tolerable\u02ee to \u02eeminimum effective\u02ee treatment","volume":"2","author":"Veronesi","year":"2012","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2019.01.219_bib22","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1245\/s10434-017-6016-y","article-title":"The optimal treatment plan to avoid axillary lymph node dissection in early-stage breast cancer patients differs by surgical strategy and tumor subtype","volume":"24","author":"Pilewskie","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2019.01.219_bib23","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol"},{"issue":"9712","key":"10.1016\/j.ejso.2019.01.219_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ejso.2019.01.219_bib25","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2001.19.22.4224","article-title":"Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902","volume":"19","author":"van der Hage","year":"2001","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2019.01.219_bib26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2019.01.219_bib27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","article-title":"Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure","volume":"261","author":"Donker","year":"2015","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.ejso.2019.01.219_bib28","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1245\/s10434-017-6270-z","article-title":"Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA trial) : a new tool to guide the excision of the clipped node after neoadjuvant treatment","volume":"25","author":"Siso","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2019.01.219_bib29","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ejso.2016.03.023","article-title":"Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: a nationwide survey study in The Netherlands","volume":"42","author":"Vugts","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2019.01.219_bib30","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","article-title":"How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study","volume":"23","author":"Mamtani","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2019.01.219_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejrad.2014.09.020","article-title":"Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review","volume":"84","author":"Schipper","year":"2015","journal-title":"Eur J Radiol"},{"issue":"12","key":"10.1016\/j.ejso.2019.01.219_bib32","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.ejrad.2016.10.030","article-title":"Routine use of standard breast MRI compared to axillary ultrasound for differentiating between no, limited and advanced axillary nodal disease in newly diagnosed breast cancer patients","volume":"85","author":"van Nijnatten","year":"2016","journal-title":"Eur J Radiol"},{"issue":"10","key":"10.1016\/j.ejso.2019.01.219_bib33","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1245\/s10434-013-3118-z","article-title":"Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer","volume":"20","author":"Hieken","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"1052","key":"10.1016\/j.ejso.2019.01.219_bib34","doi-asserted-by":"crossref","first-page":"20150143","DOI":"10.1259\/bjr.20150143","article-title":"Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and 1\u2078F-FDG PET\/CT","volume":"88","author":"You","year":"2015","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ejso.2019.01.219_bib35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.breast.2016.11.012","article-title":"Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - results from the multi-center SENTINA trial","volume":"31","author":"Schwentner","year":"2017","journal-title":"Breast"},{"issue":"30","key":"10.1016\/j.ejso.2019.01.219_bib36","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2014.57.8401","article-title":"Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American college of surgeons oncology group Z1071 trial (alliance)","volume":"33","author":"Boughey","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2019.01.219_bib37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.breast.2017.05.015","article-title":"The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT)","volume":"35","author":"Peppe","year":"2017","journal-title":"Breast"},{"issue":"8","key":"10.1016\/j.ejso.2019.01.219_bib38","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10585-018-9938-2","article-title":"Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST)","volume":"35","author":"Liedtke","year":"2018","journal-title":"Clin Exp Metastasis"},{"issue":"5","key":"10.1016\/j.ejso.2019.01.219_bib39","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.24887","article-title":"Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast","volume":"116","author":"Schwartz","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejso.2019.01.219_bib40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejso.2015.11.019","article-title":"Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment","volume":"42","author":"Galimberti","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2019.01.219_bib41","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.ejso.2017.07.023","article-title":"Sentinel node biopsy after primary chemotherapy in cT2 N0\/1 breast cancer patients: long-term results of a retrospective study","volume":"43","author":"Martelli","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2019.01.219_bib42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10549-017-4157-0","article-title":"Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases","volume":"163","author":"van Nijnatten","year":"2017","journal-title":"Breast Canc Res Treat"},{"issue":"3","key":"10.1016\/j.ejso.2019.01.219_bib43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","volume":"264","author":"Giuliano","year":"2016","journal-title":"Ann Surg"}],"updated-by":[{"DOI":"10.1016\/j.ejso.2019.07.007","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000}}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319302458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319302458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T14:18:23Z","timestamp":1558102703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798319302458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0748798319302458"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2019.01.219","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejso.2019.07.007","asserted-by":"object"}]},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2019.01.219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}